Amgen Building On Repatha Experience As It Grows In Cardiovascular, Obesity

Execs Shared Strategy At J.P. Morgan Meeting

Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.

Amgen has invested millions in physician and patient education already in support of Repatha (Shutterstock)

Amgen is no stranger to the heavy lifting required to get a new treatment for cardiovascular diseases off the ground, since its LDL cholesterol-lowering PCSK9 inhibitor Repatha (evolocumab) was not an immediate blockbuster. But now that the drug is annualizing at more than $2bn in sales, the company will use the commercialization muscles it developed for Repatha to build its strategies for Lipoprotein(a)-reducing olpasiran and obesity candidate maridebart cafraglutide (MariTide, formerly AMG 133).

Key Takeaways
  • Amgen’s experience with PCSK9 inhibitor Repatha’s development as an LDL cholesterol-lowering treatment has informed the company’s planned cardiovascular disease growth strategy.
  • The...

CEO Robert Bradway highlighted Repatha, olpasiran and MariTide during his J.P. Morgan Healthcare Conference presentation on 13 January and Amgen executives discussed the company’s strategy for the product and new...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By 

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By 

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By 

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By 

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Market Access

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By 

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.